Trump's touting of an unproven autism drug surprised many
MATTHEW PERRONE
Associated Press
Updated
1 of 3
President Donald Trump speaks Monday in the Roosevelt Room of the White House in Washington, as, from left, Dr. Jay Bhattacharya, director of the National Institutes of Health, Dr. Marty Makary, commissioner of the Food and Drug Administration, Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services administrator Dr. Mehmet Oz, Dr. Dorothy Fink, acting assistant secretary for health and Jackie O'Brien listen.Â
Mark Schiefelbein, Associated Press
Dr. Marty Makary, commissioner of the Food and Drug Administration, and Dr. Jay Bhattacharya, director of the National Institutes of Health, listen Monday as President Donald Trump speaks in the Roosevelt Room of the White House in Washington.Â
Mark Schiefelbein, Associated Press
President Donald Trump speaks Monday in the Roosevelt Room of the White House in Washington.Â
WASHINGTON — When President Donald Trump's administration announced it would repurpose an old, generic drug as a new treatment for autism, it came as a surprise to many experts — including the physician who suggested the idea to the nation's top health officials.
President Donald Trump speaks Monday in the Roosevelt Room of the White House in Washington, as, from left, Dr. Jay Bhattacharya, director of the National Institutes of Health, Dr. Marty Makary, commissioner of the Food and Drug Administration, Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services administrator Dr. Mehmet Oz, Dr. Dorothy Fink, acting assistant secretary for health and Jackie O'Brien listen.Â
Dr. Marty Makary, commissioner of the Food and Drug Administration, and Dr. Jay Bhattacharya, director of the National Institutes of Health, listen Monday as President Donald Trump speaks in the Roosevelt Room of the White House in Washington.Â
